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Micro Abstract 
 
The loss of muscle is a common consequence of advanced lung cancer and impairs 
an individual’s quality of life while often shortening their time until eventual death. 
Animal models of cancer have highlighted potential mechanisms that could explain 
this debilitating loss of muscle mass, but the impact of cancer on muscle metabolism 
in lung cancer patients has been less well explored, particularly in advanced stages 
of the disease. To address this, we surveyed in muscle biopsies obtained from late-
stage non-small cell lung cancer patients the impact of the disease on a number of 
key metabolic processes; observing changes consistent with an impairment of 
muscle to manufacture new muscle proteins and a reduction in the amount of lipid 
stored in muscle cells. Collectively, it highlights the need to understand the potential 
contribution of impaired fat metabolism and muscle protein synthesis in the 
development of lung cancer-induced muscle loss. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Abstract 
Introduction: Loss of muscle is common in patients with advanced non-small 
cell lung cancer (NSCLC), and contributes to the high morbidity and mortality of this 
group. The exact mechanisms behind the loss of muscle are unclear. Methods: To 
investigate this, 4 patients with stage IV NSCLC meeting the clinical definitions for 
sarcopenia and cachexia were recruited, along with 4 age-matched healthy 
volunteers. Following an overnight fast, biopsies were obtained from the vastus 
lateralis and key components associated with inflammation and the control of muscle 
protein, carbohydrate and fat metabolism assessed. Results: Compared to healthy 
volunteers, significant increases in mRNA levels for interleukin-6 and NFκB 
signalling were observed in NSCLC patients along with lower intramyocellular lipid 
content in slow-twitch fibres. While a significant decrease in phosphorylation of 
mTOR signalling protein 4E-BP1 (Ser65) was observed along with a trend towards 
reduced p70 S6K (Thr389) phosphorylation (P=0.06), there was no difference 
between groups for mRNA levels of MAFbx and MuRF1, chymotrypsin-like activity of 
the proteasome, or protein levels of multiple proteasome subunits. Moreover, despite 
decreases in intramyocellular lipid content, no robust changes in mRNA levels for 
key proteins involved in insulin signalling, glycolysis, oxidative metabolism or fat 
metabolism were observed. Conclusions: These findings suggest that an 
examination of the contribution of suppressed mTOR signalling in the loss of muscle 
mass in late-stage NSCLC patients is warranted and reinforces our need to 
understand the potential contribution of impaired fat metabolism and muscle protein 
synthesis in the aetiology of cancer cachexia. 
Key words: Muscle protein synthesis; proteolysis; cachexia; mTOR signalling; 
ubiquitin proteasome system  
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Introduction 
 
Cachexia, characterised by the unintended loss of skeletal muscle mass, is common 
in patients with non-small cell lung cancer (NSCLC), with about half presenting with 
severe muscle depletion at the time of diagnosis 1. Of concern, cachexia is 
associated with reductions in tolerance to anticancer therapy, quality of life and 
survival 2. Given that no standard treatment exists for cancer cachexia and it cannot 
be reversed by conventional nutritional support, it represents a major unmet clinical 
need. For logical developments in therapy to occur, the physiological and cellular 
mechanisms which lead to the loss of muscle mass in these patients need to be 
better understood. 
 While reports of the impact of cancer on muscle metabolism in patient 
populations are limited, evidence accumulated to date suggests cancer-induced 
alterations in muscle metabolism are reversed on cancer resection 3, 4. This 
implicates cancer burden as a key driver in cancer cachexia. NSCLC, in common 
with a number of cancers, is associated with the increased synthesis and elevated 
circulating concentrations of pro-inflammatory cytokines including tumor necrosis 
factor-α (TNFα) and interleukin-6 (IL6) 5. Animal and cell culture work has routinely 
demonstrated inflammation to negatively impact upon multiple facets of muscle 
metabolism (see 6) and thus inflammation may act as a central causative feature for 
the cachexia that develops with cancer progression. In support, the administration of 
an IL6 receptor antibody to impair the action of IL6, has been shown to negate 84% 
of the muscle atrophy typically observed in the gastrocnemius of a murine model of 
cancer cachexia 7. 
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 The loss of muscle mass is thought to develop as a consequence of 
enhanced muscle proteolysis, predominantly through activation of the ubiquitin 
proteasome system (UPS), with a concomitant suppression of muscle protein 
synthesis 8. Specifically, a reduction in mTOR signalling has been reported in the 
Apc(Min/+) mouse model of cancer, with hypo-phosphorylation of the downstream 
targets p70-S6k and 4E-BP1 9 which would be projected to lead to reduced initiation 
of translation 10. Importantly, the suppression of mTOR signalling parallels the fall in 
muscle protein synthesis and muscle mass in experimental cancer cachexia 9, and a 
dose-dependent suppression of IL6 on mTOR activity has been reported 11, 
suggesting it plays a key role. Likewise, a number of studies in animals and in 
patients with various cancers have reported an increase in components of the UPS 
12-14
, including increased transcription of the two ubiquitin ligases, MuRF1 and 
MAFbx (atrogin-1), which appear instrumental in the specific targeting of muscle 
proteins for degradation by the 26S proteasome 15, 16. Reports of IL6 receptor 
antibody administration preventing proteasome activity and muscle atrophy in an 
experimental model of cancer cachexia 7 viewed in conjunction with the ability of 
pharmacological inhibition of the proteasome pathway to blunt cancer cachexia 17, 
highlights the central role ubiquitin-proteasome mediated proteolysis is thought to 
play in the progression of cancer cachexia. However, of studies that have attempted 
to examine components of the proteasome pathway in patients with NSCLC and 
none have demonstrated an increase in UPS activity 5, 18, 19. Thus, the contribution of 
ubiquitin-proteasome mediated proteolysis in NSCLC cachexia remains unclear. 
 In addition to the described changes in protein metabolism, cancer induced 
alterations in muscle carbohydrate and lipid metabolism could be underpinning 
impaired muscle function experienced by cancer patient populations. The 
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development of peripheral insulin resistance is commonly observed in experimental 
cancer models and in cancer patients 20. Inflammation, including via action of the 
cytokines IL6 and TNFα, has been associated with an impairment of the AKT insulin 
signalling pathway. Likewise, administration of IL-6 to healthy individuals to increase 
plasma IL6 concentrations leads to profound increases in muscle lipolysis and fatty 
acid oxidation 21. However, the impact of late-stage NSCLC on muscle metabolism 
remains poorly defined. 
 The purpose of this study was to examine the impact of late-stage NSCLC on 
inflammatory signalling and key parameters that regulate muscle protein, fat and 
carbohydrate metabolism, thereby providing unique insight into the potential 
mechanisms responsible for cachexia and functional impairment in this patient 
population. 
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Methods 
 
Ethical Approval 
 Research was conducted in accordance with the Declaration of Helsinki 
(2008) of the World Medical Association regarding the use of human subjects in 
medical research and approval gained from the East Midlands Research Ethics 
Committee (ref. 09/H0403/65). Participants were given a full explanation of the study 
and provided written informed consent. 
 
Participants 
 Patients were recruited from an existing study examining the effectiveness of 
an exercise regimen in adults scheduled to receive first-line palliative chemotherapy 
following a diagnosis of advanced NSCLC 22. Recruited patients underwent the 
protocol described below before beginning chemotherapy or undertaking the 
exercise intervention required of the parent study 22. Patients had an Eastern 
Cooperative Oncology Group performance status 23 between 0 and 2. Lumbar CT 
muscle mass was determined using diagnostic computed tomography images and 
SliceOMatic analysis software following previously described methods 24. 
Appendicular muscle mass was determined using dual-energy X-ray absorptiometry 
(LUNAR Prodigy Advanced, GE Lunar, USA) with the accompanying encore 
software (Version 13.6) using standard imaging and positioning protocols 25. Mean 
daily protein (g.day-1) and energy (kJ.day-1) intake were calculated using Compeat™ 
(version 5.8.0, Nutrition Systems UK) based on a prospective 3-day diary which 
included one weekend and two week days. Relevant anthropometric and blood 
pathology results were obtained from the patients’ medical records. Healthy 
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volunteers of a similar age, gender, smoking history and physical activity level to the 
patient group, and without a history of metabolic or cardiovascular disease or 
vegetarian diet, were recruited (Table 1). Healthy volunteers underwent a battery of 
blood tests including full blood count, liver function tests, and urea and electrolytes, 
with all values found to be within normal ranges. Physical activity level was matched 
using the 12-item Modified Baecke Questionnaire 26, which summarizes habitual 
physical household (e.g. housework, meal preparation and stair climbing) and leisure 
activities in the previous year. The questionnaire was selected as it has been shown 
to be a valid and repeatable assessment of physical activity, suited to the older 
population, and has previously been used to match volunteers to NSCLC patient 
groups 27. 
 
Study protocol 
 Participants attended the laboratory facility at 09:00h following an overnight 
fast and having abstained from alcohol or vigorous exercise the previous day. While 
resting in a semi-supine position, a venous blood sample was taken from a vein in 
the antecubital fossa region into pre-chilled EDTA tubes. Samples were kept on ice 
and within 30 mins of collection centrifuged at 3,000g for 10 mins, with the resultant 
plasma stored at -80°C prior to analysis. Afterward s, a single percutaneous muscle 
biopsy specimen was obtained from the vastus lateralis muscle under local 
anaesthetic according to the method described by Bergstrom 28. The muscle sample 
was snap frozen and stored in liquid nitrogen prior to qPCR and western blot 
analysis. 
 
Plasma IL6 and TNFα concentration by ELISA 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
 The cytokines TNFα and IL6 are both known to be systemically elevated in a 
multitude of cancers, including in NSCLC patients 5. To determine changes in 
systemic circulating levels of IL6 and TNFα in NSCLC patients, protein concentration 
of both cytokines were examined in plasma samples using commercially available 
enzyme-linked immunosorbent assays (Arcus Biologicals, Italy). Samples were run 
in duplicate along with standards of known concentration according to the 
manufacturer’s protocol. At the end of the assay, the absorbance at 450 nm was 
determined for each well of the ELISA plate using a spectrophotometer (Molecular 
devices, USA). 
 
qPCR 
 Total RNA was extracted from 30 mg of muscle tissue using TRIzol reagent 
(Invitrogen, UK) and quantified on a nanoDrop spectrophotometer. cDNA was 
subsequently synthesised using the SuperScript III commercial cDNA synthesis kit 
(Invitrogen, UK) according to the manufacturer’s protocol. Low-density microfluidic 
cards containing PCR primer pairs and Taqman probes for a number of regulatory 
genes associated with carbohydrate, fat and protein metabolism were utilised and 
analysed on a 7900 HT Real-Time PCR System (Applied Biosystems, USA). MAFbx 
and MuRF1, two ubiquitin ligases that appear central to muscle atrophy in a number 
of cachectic states 16 and myostatin, a negative regulator of muscle growth, were not 
represented on the microfluidic card and were instead analysed separately. In short, 
PCR primers and reporter probes labelled with a 6-carboxyfluorescein (FAM) 
fluorophore at the 3’ end and a tetramethylrhodamine (TAMRA) quencher at the 5’ 
end, were purchased for MAFbx (forward: 5’ CAGCTCTGCAAACACTGTCACA 3’; 
reverse: 5’ GAGCAGCTCTCTGGGTTATTGG 3’; probe: 5’ 
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AAGGGCACTGACCATCCGTGCAC 3’), MuRF1 (forward: 5’ 
GGAGCCACCTTCCTCTTGACT 3’; reverse: 5’ CTCAAAGCCCTGCTCTGTCTTC 3’; 
probe: 5’ AACTCATCAAAAGCATTGTGGAAGCTTCCAA 3’), myostatin (forward: 5’ 
TGCTGTAACCTTCCCAGGAC 3’; reverse: 5’ GGTGTGTCTGTTACCTTGACCTC 
3’; probe: 5’ AGGAGAAGATGGGCTGAATCCGTTTTT 3’) and the housekeeping 
gene hydroxymethylbilane synthase (forward: 5’ ACGATCCCGAGACTCTGCTTC 3’; 
reverse: 5’ GCACGGCTACTGGCACACT 3’ ; probe : 5’ 
CAGCCTCCTTCCAGGTGCCTCAGG 3’) from EuroFins, UK. Hydroxymethylbilane 
synthase was also represented on the microfluidic cards and was utilised as a 
housekeeping gene throughout the two qPCR approaches adopted. Relative 
quantification of MAFbx, MuRF1 and myostatin was performed on an ABI Prism 
7000 Sequence Detection System (Applied Biosystems, USA). Obtained data was 
analysed using the comparative Ct method (∆∆Ct) for the relative quantification of 
gene expression. No significant difference was observed between groups for cycle 
threshold values of the housekeeping gene (data not shown). 
 
Western blotting 
 Given the essential role of mTOR signalling in the control of muscle protein 
synthesis, and the ubiquitin proteasome system in eliciting enhanced muscle 
proteolysis in a number of cachectic states, both were examined by western blot 
analysis in tandem to assess what impact they may be having on the regulation of 
muscle mass. In short, cytosolic proteins were extracted from 30 mg of muscle 
tissue, quantified, separated by molecular weight on a 4-12% Bis-Tris 
polyacrylamide gel by electrophoresis, and transferred to PVDF membranes 
(Amersham Biosciences, UK) using methods described in detail elsewhere 29. 
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Membranes were subsequently blocked with 5% (w/v) bovine serum albumin in 1X 
tris-buffered saline for 1 h, followed by incubation overnight with a primary polyclonal 
antibody for either AKT, mTOR, GSK3β, 4E-BP1, p70S6K (Cell Signaling 
Technology Inc., USA) or proteasome subunits α1-3; 5-7 (Biomol, USA). The 
following phospho-specific primary antibodies were also utilised: AKT Thr308, mTOR 
Ser2448, GSK3β Ser9, 4E-BP1 Ser65 and p70S6K Thr389 (Cell Signaling Technology 
Inc., USA). Following incubation with the primary antibody and subsequent washing 
in TBS-T, the membranes were incubated with a fluorescently-labelled anti-mouse or 
anti-rabbit secondary antibody as appropriate (Dylight® conjugate, Cell Signaling 
Technology Inc., USA) prior to digital capture on an electronic image acquisition 
system (Odyssey CLx, Licor Biosciences, USA). Band densities were determined 
using the proprietary software provided with the Odyssey scanner and normalised to 
beta-actin (Sigma, UK) protein levels to control for loading. 
 
26S Proteasomal activity 
 Proteasomal activity was measured using a method adapted from 30 and 31. In 
detail, 20 mg of muscle tissue was homogenised for 2 mins with a glass-ground 
homogeniser in a 1:20 volume of extraction buffer (50 mM Tris-HCl (pH 7.5), 5 mM 
MgCl2, 2 mM ATP, 1 mM DTT and 0.5 mM EDTA). Afterwards, the sample was 
centrifuged at 8,000g for 20 mins at 4°C. From the supernatant, 5 µl was assayed for 
proteasomal activity in 400 µl of assay buffer (50 mM Tris-HCl (pH 7.5), 40 mM KCl, 
5 mM MgCl2, 0.5 mM ATP, 1 mM dithiothreitol and 0.5 mg.ml-1 bovine serum 
albumin) by the addition of 4 µl a 10 mM solution of the fluorogenic substrate Suc-
LLVY-amc (Sigma, UK) and followed by incubation for 10 mins at 37°C. After the 
allotted time, the reaction was stopped via the addition of 1.6 ml of an 80 mM 
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potassium acetate solution (pH 4.3). Emission at 460 nm of the cleaved substrate 
was determined on the resultant solution by use of a fluorometer (F-2000, Hitachi, 
Japan) following excitation at 360 nm. Analysis of a duplicate sample treated in the 
same manner as above but including the proteasome-specific inhibitor epoxomicin 
(20 µM; Sigma, UK) in the reaction mixture completely prevented cleavage of the 
fluorogenic substrate, confirming specificity of the reaction for proteasomal-
dependent proteolysis.  
 
Pyruvate dehydrogenase complex activity 
 Approximately 5 mg of snap-frozen muscle that had remained stored under 
liquid nitrogen conditions was assayed for pyruvate dehydrogenase activity (PDCa) 
using an established radioisotopic assay 32. PDCa was expressed as the rate of 
acetyl-CoA formation (mmol.min-1 at 37°C) normalised for protein content in the 
biopsy specimens. 
 
Assessment of intramyocellular lipid (IMCL) content 
 To establish if chronic and gross changes in muscle fat metabolism had 
occurred with NSCLC, the percentage area occupied by lipid droplets in muscle 
fibres was examined. Frozen muscle was sectioned (10 µm) and fixed in 4% 
paraformaldehyde phosphate buffered saline (pH 7.4) prior to assessment of 
intramyocellular lipid content using the lipophilic dye, LD540 (synthesised by the 
University of Nottingham School of Chemistry 33). To accomplish this, sectioned 
samples were incubated at room temperature for 1 hour with 3 µM LD540 in 
dimethylsulfoxide, followed by 3 washes in PBS before being embedded in an 
antifade reagent (ProLong Gold, Life Technologies, Paisley, UK). LD540 stained lipid 
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droplets were visualised at x40 magnification as 1 µm z-stacks with the aid of a 561 
nm laser coupled to a TCS SP2 confocal microscope (Leica Microsystems, 
Heidelberg, Germany). The area of the fibre covered by fluorescence was calculated 
using the commercial Volocity software package (version 6.3; PerkinElmer, 
Cambridge, UK) and fibre-type identified via staining with an antibody raised against 
the human adult form of slow myosin heavy chain (A4.951, developed by Dr. Blau 
34). The Volocity software was used to calculate the intramuscular lipid content 
normalised to fibre area on a fibre-type specific basis. 
 
Statistical analysis 
 Small sample sizes as employed in the current study are common in basic 
science studies requiring the use of invasive muscle sampling techniques in 
chronically ill small patient populations (e.g. 35, 36). As such, between group 
comparisons were made using an unpaired t-test as it has been previously 
demonstrated that the t-test is a valid approach and outperforms the non-parametric 
Welch test when small sample sizes are used 37. Similarly, given the number of 
patients recruited, correcting the qPCR data for multiple comparisons would lead to 
an increased incidence of type-II errors, masking genuine gene expression changes. 
As such, data is reported uncorrected and instead, potential type I errors are 
considered informally at the level of interpretation by looking at changes across the 
spectrum of genes analysed, a valid approach when performing multiple 
comparisons 38. All statistical tests were performed using the Prism v6.02 statistical 
software package for Windows (GraphPad Software Inc., San Diego, USA) with data 
reported as means ± SEM and statistical significance accepted when P ≤ 0.05. 
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Results 
 
Demographic and other details 
 The characteristics of the patient and control subjects are described in Table 
1. Patients with NSCLC satisfied recommended criteria for cachexia 2 and 
sarcopenia 24 with lumbar and/or appendicular muscle mass below normal reference 
ranges (L3 CT mass: males < 52.4 cm2.m-2, females < 38.5 cm2.m-2; appendicular 
lean mass: males < 7.26 kg.m-2, females < 5.45 kg.m-2; 2, 24). Moreover, patients had 
lost a mean of 9 ± 2% of their body weight over the preceding 6-months. Compared 
to healthy volunteers, patients with NSCLC had lower BMI and activity levels but this 
was not statistically significant. The latter is perhaps not surprising given the well-
reported issues faced with obtaining accurate self-reported measures of physical 
activity 39 Analysis of dietary intake revealed patients with NSCLC to have a positive 
protein balance (38 ± 21 g.day-1) and a calorie intake marginally under predicted 
requirements (-72 ± 241 kJ.day-1). Given that a notable proportion of late-stage lung 
cancer patients fail to experience cancer anorexia (>35%)40, and that these patients 
were fit enough to undergo subsequent palliative chemotherapy, the general ability 
of the NSCLC patients to mostly maintain protein and calorie intake isn’t perhaps 
surprising. The median survival time of patients from time of their study visit was 23 
weeks (range 15-35 weeks). 
 
Systemic cytokine and muscle inflammatory marker levels 
 Compared to healthy volunteers, patients with NSCLC had a significantly 
higher plasma IL6 concentration and exhibited a trend towards increased plasma 
TNFα concentrations (P = 0.07) (Fig. 1A and 1B). Because skeletal muscle can also 
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be a significant source of IL6 and TNFα production, either from invading neutrophil 
and macrophage cell populations or the muscle cells themselves (27), we also 
determined the expression of IL6 and TNFα mRNA within muscle biopsy specimens. 
Compared to healthy control subjects, patients with NSCLC had a statistically 
significant 2.6-fold increase in IL6 muscle mRNA expression (Fig. 1C), but TNFα 
mRNA levels were equivalent between groups. NSCLC was also associated with 
significantly higher mRNA levels for examined components of the NFκB pro-
inflammatory signalling pathway, NFκB1 and NFκB3 (RELA), while mRNA levels of 
the NFκB signalling pathway inhibitor, IκK-α, was also greater in muscle of NSCLC 
patients. 
 
Muscle protein metabolism and the regulation of muscle size 
 Compared to the healthy volunteers lower mTOR protein and Ser2448 
phosphorylation levels were observed in the patients with NSCLC but this was not 
statistically significant (Fig. 2A), with no difference in phosphorylation state 
(phosphorylation:total protein) observed between groups. In contrast, the 
phosphorylation state of residue Ser65 of the downstream protein 4E-BP1 was 
significantly lower in the muscle of NSCLC patients (Fig. 2B) together with a trend 
towards lower p70 S6K Thr389 phosphorylation (P = 0.07; Fig. 2C). There were no 
significant differences in 4E-BP1 and p70 S6K muscle protein levels between 
NSCLC patients and healthy controls (Fig. 2B and 2C respectively). 
 Messenger RNA levels of MAFbx, MuRF1 and myostatin did not differ 
between NSCLC patients and control subjects (Fig. 2D). In keeping with the failure of 
NSCLC to enhance MAFbx and MuRF1 expression, protein levels of α1-3 and 5-7 
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subunits of the proteasome, and chymotrypsin-like activity of the 26S proteasome, 
were unaltered in the muscles of patients with NSCLC (Fig. 2E and 2F respectively). 
 
Insulin signalling and carbohydrate metabolism 
 Examination of mRNA levels for several components of the insulin signalling 
pathway, revealed NSCLC was associated with significantly enhanced levels of both 
AKT and GSK-3β in the muscle of affected patients (Fig. 3A). However, this did not 
translate into changes at the total protein level. Muscle samples from NSCLC 
patients displayed significantly lower levels of AKT protein compared to healthy 
volunteers (Fig. 3B), while absolute phosphorylation levels of AKT at residue Thr308 
did not differ between groups; as a result, the phosphorylation state of AKT was 
significantly increased. Similarly, the protein level of the downstream kinase GSK3β 
was equivalent between NSCLC patients and control subjects (Fig. 3C), but on 
determination, a significant increase in the phosphorylation state of GSK3β in 
NSCLC patients was observed despite similar degrees of absolute phosphorylation 
between groups. Similarly, no differences were observed for mRNA levels of several 
genes intimately associated with carbohydrate metabolism (Fig. 4A) or oxidative 
metabolism (Fig. 4B). In further support, rates of muscle pyruvate decarboxylation 
activity (PDCa), a pivotal regulator of acetyl-CoA formation from pyruvate for 
utilisation by the Kreb’s cycle, was comparable between groups (Fig. 4C). 
 
Fat metabolism 
 NSCLC was associated with a lower area of the muscle fibre occupied with 
lipid in slow- but not fast-twitch muscle fibres (Fig. 5A; P<0.05). However, with the 
notable exception of Long-chain acyl CoA synthetase where increased mRNA levels 
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were observed (Fig. 5A), late-stage NSCLC was not associated with alterations in 
the expression of multiple key genes associated with the regulation of fat metabolism 
(Fig. 5D). 
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Discussion 
 
 The impact of late-stage cancer on muscle metabolism in patients remains 
largely unknown. Here we demonstrate for the first time that in stage IV NSCLC 
patients with cachexia and increased plasma IL6 concentrations, only modest 
changes in key transcriptional and signalling events underpinning carbohydrate, fat 
and protein metabolism are observed. Moreover, they do not explain the pronounced 
cachexia or decreased muscle lipid accumulation seen in these patients reinforcing 
the essential need to initiate treatments aimed at preventing cachexia early in the 
disease process before cachexia becomes evident. 
 It has been suggested that hypermetabolism and activation of muscle 
proteolytic pathways are confined to the early stages of the disease 41, and resolve 
on removal of tumour burden 3, 4. Our results are in agreement with the proposed 
dynamic nature of cancer cachexia and provide the first insight that latter stages of 
NSCLC do not appear defined by substantial changes in muscle metabolism despite 
the prevalence of systemic and localised markers of inflammation. Our findings thus 
demonstrate the complex interplay that exists between tumour burden and 
metabolism in distal tissues and which likely changes over time. 
 While myostatin  acts as a negative regulator of muscle mass 42, we could find 
no evidence that its expression was altered in the muscle samples of late-stage 
NSCLC patients; a finding that is in keeping with the reports of others from studies 
performed in both lung 43 and gastric cancer patients 43, 44. Likewise, our inability to 
detect any indication of increased ubiquitin proteasome system-mediated proteolysis 
corroborates recent reports by others that MuRF1 and MAFbx are not elevated in 
late stage NSCLC cachectic patients 19. It is interesting to note that multiple reports 
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have failed to identify any traditional indicator of increased muscle proteasome-
mediated proteolysis in NSCLC patients at various stages of cachexia 5, 18. In 
contrast, while gastric cancer patients undergoing tumour resection show basal 
levels of atrophy gene expression compared to patients undergoing abdominal 
surgery for benign disease 44, 45, markers of increased ubiquitin proteasome system 
activity appear increased and moreover, dependent on the degree of cachexia 
present 12. Collectively, this evidence suggests that the recruitment of proteasome-
mediated proteolysis may be specific to certain cancer-types or clinical scenarios 
(e.g. when cancer-induced anorexia is evident). While ubiquitin proteasome-
mediated proteolysis is generally considered the principal mechanism by which 
muscle atrophy proceeds in cachectic states (see 46), our findings do not preclude 
proteolysis occurring via an alternative route. Indeed, previous observations of 
increased transcription of proteases involved in lysosomal-mediated protein 
breakdown in the muscle of lung cancer patients 5, highlights the need to consider 
more widely the processes by which atrophy is occurring in NSCLC patients. 
 An alternative mechanism that may contribute to the loss of muscle mass 
during NSCLC is a suppression of muscle protein synthesis via inhibition of mTOR 
signalling, where mTOR acts as a nutrient sensor activating muscle protein synthesis 
during periods of nutrient availability 47. In patients with NSCLC, reductions in mTOR 
protein and phosphorylation levels were observed in addition to reduced p70 S6K 
and 4E-BP1 phosphorylation, albeit only for the latter was the difference statistically 
significant. The collective consequences of reduced p70 S6K and 4E-BP1 
phosphorylation would be a reduced drive for muscle protein synthesis 48. However, 
reports that acute mTOR inhibition via rapamycin administration does not impact on 
postabsorptive rates of muscle protein synthesis in healthy humans 49, questions the 
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impact of the observed reduction in mTOR signalling on the induction of cachexia. In 
contrast, given the essential role of mTOR in eliciting increases in muscle protein 
synthesis during hyperaminoacidemia 49 or following contractile activity 50, if 
reductions in mTOR activity persisted following meal consumption or physical activity 
it would be anticipated to lead to pronounced blunting of the protein synthetic 
response in NSCLC patients. Recent evidence from a feeding study utilising patients 
with operable colorectal cancer, provide credence to this suggestion, where the 
provision of amino acids was seen to stimulate muscle protein synthesis in healthy 
age-matched controls but not in the patient population 4. Likewise, similar 
observations have been seen in cachectic cancer patients during intravenous protein 
provision 51. Collectively, this highlights the pressing need to understand the 
metabolic response seen to feeding and physical activity in NSCLC patients and 
whether it persists into the late stages of the disease. 
 In many cancers, the catabolism of body fat reserves is common and occurs 
in response to potential declines in food intake concomitant to hypermetabolism 52. 
Despite the high occurrence of fat catabolism in cancer patient populations, the 
impact of cancer on human muscle fat metabolism or muscle lipid accumulation is 
poorly understood. Here we show that late-stage NSCLC is associated with a 
significant reduction in lipid accumulation in slow-twitch fibres, where oxidative 
metabolism of fatty acids is likely to dominate. Moreover, in the absence of a robust 
induction of transcriptional events previously associated with altered muscle fat 
metabolism in humans 53, it reinforces the notion that gross changes in fat 
metabolism occurred early in the disease process and had rectified at time of study 
participation, with decreased lipid accumulation acting as a remnant of earlier 
changes. Given the low subject numbers employed in the current study, some 
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caution must be applied to this finding; previous reports of increased intramyocellular 
droplets in rectus abdominis muscle being associated with cancer cachexia 54, 
contrast with the observations reported here. However, their use of gastrointestinal 
cancer patients in conjunction with patients undergoing elective surgery as control 
subjects, use of a non-ambulatory muscle for examination, in addition to their failure 
to control for age (it is well known that IMCL increases with age) between subject 
groups, makes any direct comparison difficult. Nevertheless, there was a clear 
relationship between loss of fat mass and increased IMCL 54 suggesting a lipolysis-
mediated imbalance between skeletal muscle fatty acid delivery and oxidation. The 
later stage cancer, lower BMI and reduced IMCL in the patients of the present study 
would thus suggest that skeletal muscle fatty acid oxidation has outweighed delivery 
and the muscle is in a state of overt undernutrition. Interestingly, it appeared that 
PDCa was lower in the face of greater PDK4 mRNA expression, which would fit with 
a skeletal muscle undernutrition and insulin resistance, although this failed to reach 
statistical significance 55. In common with a number of disease states where chronic 
inflammation and IMCL accumulation is evident, cancer has been associated with 
the development of insulin resistance 20, thereby impacting on carbohydrate 
metabolism in peripheral tissues. To date, despite the potential contribution to 
muscle fatigue, a comprehensive evaluation of the impact of late-stage NSCLC on 
muscle carbohydrate metabolism remains unexplored. However, while no index of 
insulin sensitivity was assessed in the current study and subject numbers were small 
increasing the probability of type II errors, NSCLC failed to have a consistent effect 
synonymous of insulin resistance on insulin signalling or transcriptional regulation of 
key genes involved in glycolysis or oxidative metabolism, which would perhaps fit 
with the lower IMCL. Notably, these observations were made in the fasted state and 
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further research is required to establish if NSCLC has an impact when subjects are 
in the postprandial state to determine if insulin resistance coincides with anabolic 
resistance. 
 
Limitations 
 While the data reported provides a unique insight into the metabolic 
consequences of late-stage NSCLC on muscle, they are the result of observations 
obtained from a limited number of patients. Nonetheless our findings highlight 
important features of NSCLC-related cachexia worthy of further investigation and 
identify several gaps in our understanding. Given our findings, future work should 
consider examining NSCLC patients with and without cachexia and incorporate 
detailed measures of muscle metabolism utilising robust stable-isotope 
methodologies even though the additional invasive nature of the procedures and the 
prolonged laboratory visits required, may represent additional challenges to the 
recruitment of patients with advanced cancer. 
 
Conclusions 
 Our findings provide insight into the metabolic changes evident in skeletal 
muscle during late-stage NSCLC and contributes to the mounting evidence that the 
ubiquitin-proteasome system does not play a primary role in the loss of muscle mass 
in NSCLC patients. Moreover, it highlights our need to greater understand the 
contribution of impaired fat metabolism and muscle protein synthesis in the aetiology 
of cancer cachexia.   
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Clinical Practice Points 
The loss of muscle mass is a common consequence of non-small cell lung 
cancer (NSCLC), which can substantially impact on a patient’s quality of life and their 
ability to adhere to prescribed chemotherapy treatments. Moreover, a significant 
number of individuals are diagnosed in the later stages of disease where weight loss 
and muscle atrophy are already established. Despite this, the impact of late-stage 
NSCLC on muscle metabolism and associated mechanisms are largely unknown but 
represent a crucial prerequisite for the development of effective treatments against 
cachexia in these patients. Based on work performed in animal models of cancer 
cachexia, it would be anticipated that the loss of muscle mass during NSCLC is 
largely a consequence of enhanced rates at which muscle proteins are broken down 
via increased ubiquitin-proteasome system activity. In stark contrast, our current 
report demonstrates that blunted mTOR signalling, an essential pathway for driving 
the synthesis of new muscle protein, is reduced in the muscle of NSCLC patients 
and a likely culprit for the loss of muscle mass in these patients, while markers of 
ubiquitin-proteasome system activity remain unaltered. Furthermore, we provide the 
first evidence that late-stage NSCLC is associated with reduced intramyocellular lipid 
content, the consequences of which remain to be characterised. Collectively, these 
observations reinforce the notion that treatments aimed at reducing cachexia during 
late-stage NSCLC should be focussed on restoring cellular processes responsible 
for promoting the synthesis of muscle proteins. Speculatively, combined resistance 
exercise and protein supplementation may represent one such strategy.  
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Table 1: Subject characteristics 
 
 Control subjects (n=4) NSCLC patients (n=4) 
Age 71 ± 2 73 ± 3 
Male:Female 2:2 1:3 
BMI (kg.m-2) 26.6 ± 2.1 21.7 ± 1.9 
Diagnosis - Adenocarcinoma (n=2) 
Squamous cell (n=2) 
Stage - Stage IV (n=4) 
% weight loss over 6 
months 
0 (†) 9 ± 2 
Lumbar CT mass (cm2.m-2) - 35.5 ± 2.8 
Appendicular mass (kg.m-2) - 5.44 ± 0.34  
C-reactive protein (mg.L-1) - 68.3 ± 34.5 
Albumin (g.L-1) - 32.5 ± 3.2 
Energy balance (kJ.day-1) - -72 ± 241 
Protein balance (g.day-1) - 38 ± 21 
12-item Modified Baecke 
Questionnaire 
(median(range)) 
5 (4-12) 2 (2-6) 
All values are means ± SEM unless otherwise stated. (†) Self-reported as no weight 
loss over the previous 6 months.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
34 
 
Figure 1: Circulating concentrations and localised mRNA levels of proteins 
associated with inflammation in cancer cachexia. Plasma concentrations of 
TNFα and IL6 (A and B respectively) in late-stage NSCLC patients and age-matched 
healthy controls as determined by ELISA. Localised mRNA levels of transcripts 
encoding the two cytokines and components of NFκB signalling were determined in 
muscle specimens obtained from the same subjects (panel C) with expression in 
cancer patients normalised to healthy control values. Bars represent average values 
± SEM with * denoting significantly different from control (P≤0.05). 
 
Figure 2: Effect of late-stage NSCLC on regulators of muscle protein 
metabolism.  Total protein, absolute degree of phosphorylation, and 
phosphorylation status (phosphorylated:total protein) for A) mTOR Ser2448, B) 4E-
BP1 Thr389, and C) p70 S6K S65, determined by western blot. D) mRNA levels of 
MAFbx, MuRF1 and myostatin in NSCLC patients relative to healthy control 
subjects. E) Protein levels of proteasome subunits alpha 1-3 and 5-7 and F) ex vivo 
assessment of chymotrypsin-like activity of 26S proteasome in muscle extracts. 
Values represent mean ± SEM. * denotes significantly different from healthy controls 
(P≤0.05). Where appropriate, representative blots obtained from western blot 
analysis are provided above their respective bars. 
 
Figure 3: Impact of NSCLC on muscle insulin signalling.  A) muscle mRNA 
levels of key proteins associated with insulin signalling in NSCLC patients relative to 
healthy control subjects. Total protein, absolute degree of phosphorylation, and 
phosphorylation status (phosphorylated:total protein) for B) AKT T308 and C) GSK3β 
S9. Bars represent average values expressed in arbitrary units ± SEM. * denotes 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
35 
 
statistical significance where P≤0.05. Representative blots obtained from western 
blot analysis are provided above their respective bars. 
 
Figure 4: Consequences of NSCLC on transcription of genes associated with 
carbohydrate metabolism. Muscle mRNA levels of genes associated with A) 
glycolysis and B) oxidative metabolism in NSCLC patients expressed relative to 
healthy control subjects. To assess carbohydrate oxidation rates, the activity of the 
pyruvate dehydrogenase complex was determined ex vivo (panel C). Values 
expressed as means ± SEM. No significant differences were observed for any of the 
parameters determined (P<0.05). 
 
Figure 5: Impact of NSCLC on indices of muscle fat metabolism. A) Proportion 
of muscle fibre occupied by lipid droplets reported on a fibre-type specific basis. B) 
Representative confocal microscope images obtained from muscle sections of 
healthy individuals and NSCLC patients stained with LD540 to identify lipid droplets 
(represented in red). Images obtained at 40X magnification, with slow-twitch fibres 
stained green via the use of an antibody that identifies the slow isoform of human 
myosin heavy chain. C) Muscle mRNA levels of genes implicated in the regulation of 
fat metabolism in NSCLC subjects, expressed relative to healthy control subjects. 
Values represent mean ± SEM. * denotes significantly different from healthy controls. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
